278 filings
Page 5 of 14
8-K
acrka
11 May 20
Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress
4:01pm
8-K
j1hl9spobev
5 May 20
Fate Therapeutics Announces Changes to its Board of Directors
4:03pm
8-K
lyi c5uhidv37hto79pp
28 Apr 20
Other Events
4:23pm
D
zs6155j0
21 Apr 20
$50M in equity, sold $50M, 1 investor
3:24pm
8-K
4nqvkd8 l4aj5idv
2 Apr 20
Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies
4:55pm
DEFA14A
opii1m9cdslb6r4pug
20 Mar 20
Additional proxy soliciting materials
4:04pm
S-8
cgv5uqojfhbjg159c
2 Mar 20
Registration of securities for employees
5:04pm
8-K
2nfpde4u
2 Mar 20
Fate Therapeutics Reports Fourth Quarter 2019 Financial Results and Operational Progress with 2020 Outlook
4:01pm
8-K
vbbttond
10 Jan 20
Entry into a Material Definitive Agreement
4:01pm
8-K
whxvr sv3i1korj0el
14 Nov 19
Termination of a Material Definitive Agreement
4:01pm
8-K
1fysopp4 cjfrri9gfe
5 Nov 19
Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress
4:01pm
8-K
um0rw8
12 Sep 19
Fate Therapeutics Announces Proposed Public Offering of Common Stock
9:30pm
424B5
t1ha26 shcwku
12 Sep 19
Prospectus supplement for primary offering
9:25pm
424B5
emvw60ud
11 Sep 19
Prospectus supplement for primary offering
4:08pm
8-K/A
80yu awx3y
7 Aug 19
Fate Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Operational Progress
4:01pm
8-K
ncoz5gtrzx5x6rui
6 Aug 19
Fate Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Operational Progress
4:01pm